跳至主要内容
临床试验/NCT06172426
NCT06172426已完成不适用

Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry

Novartis Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 1,171 人开始时间: 2022年11月17日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,171
试验地点
1
主要终点
Exposure-adjusted incidence rate of PsA per 100 patient-years among PsO patients who newly initiated secukinumab

研究概览

简要总结

This was a retrospective cohort study to assess the incidence rate of psoriatic arthritis (PsA) among psoriasis (PsO) patients newly initiated on secukinumab or any biologics/apremilast (small molecule). The analysis was performed in two databases, IBM® MarketScan® database: Commercial Claims and Encounters (CCAE) and Medicare Supplemental Beneficiaries (MDCR) from 01 January 2010 to 30 June 2021 and BADBIR from 01 January 2016 to 01 September 2021.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Exposure-adjusted incidence rate of PsA per 100 patient-years among PsO patients who newly initiated secukinumab

时间窗: Up to 11.5 years

次要结局

  • Health Assessment Questionnaires - Disability Index (HAQ-DI)(Baseline)
  • Ethnicity(Baseline)
  • Height(Baseline)
  • Prior treatments(Baseline)
  • Psoriasis Area and Severity Index (PASI)(Baseline)
  • Weight(Baseline)
  • Body mass index (BMI)(Baseline)
  • Comorbidities(Baseline)
  • Time from secukinumab initiation to the first PsA diagnosis(Up to 11.5 years)
  • Age(Baseline)
  • Gender(Baseline)
  • Region(Baseline)
  • Insurance type(Baseline)
  • Hard-to-treat locations(Baseline)
  • Dermatology Life Quality Index (DLQI)(Baseline)
  • Body Surface Area (BSA)(Baseline)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验